Nobivac Lepto 2
Active substance
ATC code
Species
Dogs.
Indications
For active immunisation of dogs to reduce infection with Leptospira interrogans serogroup Canicola and Leptospira interrogans serogroup Icterohaemorrhagiae.
Specific claims:
The duration of immunity induced by the vaccine was established as at least one year. Nobivac Lepto 2 significantly reduces the number of animals which develop a urinary tract infection which can predispose to development of a carrier condition after L. Canicola and L. Icterohaemorrhagiae infection.
Dose to be administered and administration route
Subcutaneous use.
Administer 1 dose (1 ml) per animal.
Allow the vaccine to reach room temperature (15 °C – 25 °C) before use.
Sterile injection equipment should be used.
Primary vaccination course:
All dogs not previously vaccinated should be vaccinated twice 2 – 4 weeks apart.
Puppies should be at least 6 weeks of age before they receive the first vaccination.
Revaccination
A single annual booster dose is recommended.
Nobivac Lepto 2 may be used to reconstitute Nobivac DHPPi, DHP, Pi or Parvo-C as indicated in the appropriate package leaflets.
For more detailed advice on vaccination programmes and how the product may be used in conjunction with other Nobivac dog vaccines under specific circumstances, contact the company/distributor or refer to the support literature.
Adverse reactions
A transient rise in body temperature post-vaccination has been observed in rare cases during the clinical safety studies.
Dogs may show local reactions after injection in very rare cases, according to spontaneous pharmacovigilance reports. A diffuse swelling, up to 5 cm in diameter, may be observed at the site of injection for up to 4 days. Occasionally this swelling may be hard and painful, but this will diminish gradually and disappear after 2 – 3 weeks.
A transient acute hypersensitivity reaction - with signs that may include lethargy, facial oedema, pruritus, vomiting or diarrhoea - may occur shortly after vaccination in very rare cases. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening with additional signs like dyspnoea or collapse. If such reactions occur appropriate treatment is recommended.
Mild systemic signs such as lethargy and anorexia were reported very rarely.
Clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia, or immune-mediated polyarthritis have been reported in very rare cases.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
